8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022
The market's "man with a hammer" attitude toward pharmaceutical stocks has arguably created some truly compelling buying opportunities for patient investors, however. Here is a brief overview of eight pharmaceutical stocks (listed alphabetically) that have fallen way too far this year, making them top buys leading into 2022. Adaptimmune Therapeutics (NASDAQ: ADAP), a cellular immunotherapy company, has so far lost 47.4% of its value relative to its 52-week high in 2021.
